



Absolute Configuration of Lythrancine-I, -II, -III, -IV, Lythrancepine-I, -II, and -III

Recently, seven new alkaloids shown in the title were isolated from *Lythrum anceps* MAKINO, and their structures were elucidated.¹⁾ Now, their absolute configuration is discussed.

First of all, attention was paid to the nuclear magnetic resonance (NMR) spectrum of lythrancine-IV (IV), because of an effectiveness for the discussion of the stereochemistry of three (C-1, C-3, and C-4) of six asymmetric centers. The chemical shift of the proton Hc (δ 4.17) indicates that the quinolizidine ring junction is *cis* rather than *trans*.²⁾ The fact that



- lythrancine-I (I) : R¹=H, R²=H, R³=OH
 lythrancine-II (II) : R¹=Ac, R²=H, R³=OH
 lythrancine-III (III) : R¹=Ac, R²=Ac, R³=OH
 lythrancine-IV (IV) : R¹=Ac, R²=Ac, R³=OAc
 lythrancepine-I (V) : R¹=H, R²=H, R³=H
 lythrancepine-II (VI) : R¹=Ac, R²=H, R³=H
 lythrancepine-III (VII) : R¹=Ac, R²=Ac, R³=H



1) E. Fujita and Y. Saeki, *Chem. Commun.*, 1971, 368.

2) F. Bohlmann, D. Shumann, and C. Arndt, *Tetrahedron Letters*, 1965, 2705; J.P. Ferris, C.B. Boyce, and R.C. Briner, *ibid.*, 1966, 3641.

the Bohlmann absorption band³⁾ was absent in its infrared (IR) spectrum also supported it. Under expectation that the *cis*-quinolizidine moiety exists in a chair-chair conformation in the molecule, the splitting with 11 and 4 Hz of the H_C signal represents that it has an axial orientation. Moreover, an octet (J 3, 6, and 11.5 Hz) at δ 5.15 (H_B) and a narrow triplet (J 3 Hz) at δ 4.91 (H_X) show that these two hydrogens should have an axial and an equatorial orientation, respectively. This indicates a *cis*-relationship of two acetoxy groups on C-3 and C-4, and is consistent with the chemical evidence.¹⁾

Subsequently, an optical rotatory dispersion (ORD) spectrum of dehydrolythrancine-III (VIII)¹⁾ was taken. It showed a negative Cotton effect at 312 m μ , which indicated the S configuration of C-5 *i.e.* α -H_D (equatorial C-H_D to the ring A) in the formula shown.

A *trans*-relationship between H_D and H_G is clear, since *trans*-2-carboxy-6-carboxymethyl hexahydropyridine¹⁾ has been afforded on oxidation of lythrancine-II.

Consequently, the absolute configurations of five asymmetric centers were clarified; C-1: R, C-3: R, C-4: S, C-5: S, and C-9: S in lythrancine-I—IV, and all the same except C-4 in lythrancepine-I—III. The determination of the absolute configuration of the remaining asymmetric center C-11 and the final confirmation of the foregoing assignment was achieved by the following chemical conversions.

Jones' oxidation of lythrancepine-II (VI) gave an oxoproduct IX, mp 219—220°, C₂₉H₃₅O₅N, which was treated with silica gel, then was subjected to catalytic hydrogenation to give a mixture of products, from which the ketone X, mp 81—82°, C₂₉H₃₇O₅N (NMR δ 3.80, dd, J 8 and 4 Hz, C-1-H) and the desired ketone XI, mp 89—90°, C₂₉H₃₇O₅N, were isolated. The LiAlH₄ reduction of XI and subsequent formylation with acetic anhydride and formic acid afforded an O,O,N-triformate XII, mp 211—212°, C₃₀H₃₇O₇N, [α]_D +82°. This proved to be the antipode of compound XIV, mp 214—216°, C₃₀H₃₇O₇N, [α]_D -80°, derived from lythranidine (XIII), whose absolute configuration had been clarified.⁴⁾ Thus, the absolute stereochemistry of the seven bases was established as shown.

Institute for Chemical Research,
Kyoto University
Uji, Kyoto-fu, 611, Japan

EIICHI FUJITA
YUKIKAZU SAEKI

Received March 19, 1971

3) F. Bohlmann, *Chem. Ber.*, **91**, 2157 (1958).

4) E. Fujita and K. Fuji, *J. Chem. Soc. (C)*, **1971**, 1651.

Mechanism of Utilization of Pantetheine-S-Sulfonic Acid by *Bifidobacterium bifidum*

4'-Phosphopantetheine-S-sulfonic acid (P-PaSSO₃H) and 3'-dephospho-coenzyme A-S-sulfonic acid (DP-CoASSO₃H) were isolated from carrot root as growth factors for *Bifidobacterium bifidum* N4 by Yoshioka, *et al.*^{1,2)} They described that these new type of compounds

1) M. Yoshioka and Z. Tamura, *Chem. Pharm. Bull.* (Tokyo), **19**, 178 (1971).

2) M. Yoshioka and Z. Tamura, *Chem. Pharm. Bull.* (Tokyo), **19**, 186 (1971).